NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Zerion Pharma

Zerion Pharma

Private
CopenhagenHealthcare & Life Scienceshttps://www.zerion.eu/

Last Round

VC Round

Jun 30, 2026

Total Funding Raised

$8.51M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Zerion Pharma is a pharmaceutical development company that provides a proprietary formulation platform, Dispersome®, to improve the solubility and bioavailability of poorly soluble small-molecule drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

drug deliverybioavailabilitysolubility enhancementoral drug deliveryactive pharmaceutical ingredientAPImonoclonal antibodyoral biologicsamorphous solid dispersionASDdrug formulationpharma techbiotech licensingdrug developmentpill tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zerion Pharma Comparables

Compare Zerion Pharma with similar companies based on industry and business-model similarity.

Zerion Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
inflamed pharma
86%
DelAQUA Pharmaceuticals, Inc.
83%
Intract Pharma
83%

Zerion Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 30, 2026
GrantJan 12, 2026
Early FundingMay 4, 2023
Early FundingDec 14, 2021
GrantOct 1, 2020
Seed
Jun 1, 2020

Key People

Founding team and executive leadership

Korbinian Löbmann

Chief Scientific Officer And Co-founder

Founding Team

Zerion Pharma Investors

Notable investors and investment history

Zerion Pharma investors
InvestorRounds
Ligand PharmaceuticalsVC Round
Innovation Fund DenmarkGrant
Eurostars SME programmeGrant
The Export and Investment Fund of DenmarkEarly Funding, Seed, Debt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors grew 173% MoM, reaching 2.8K.

  • Jan 12, 2026

    Developing first HER2 oral monoclonal antibody for breast cancer treatment.

Zerion Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zerion Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zerion Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCopenhagen
Employee Range21
Year Founded2019
Last FundingJun 30, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.